Visão geral da empresa
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel immunotherapies designed specifically for cancer treatment. The company functions within the healthcare sector, specifically targeting the biotechnology industry, where its focus lies in advancing pipeline products such as BDC-4182, a next-generation Boltbody ISAC aimed at the tumor-associated antigen claudin 18.2 for gastric cancer applications. At its current scale, the firm maintains a market capitalization of $8.67M, generates annual revenue of $7.70M, and employs a workforce of 23 individuals. These financial metrics indicate a small-cap biotechnology enterprise that is still in the early phases of commercialization, characterized by a market valuation that reflects high-risk, high-potential development rather than established profitability.
Saúde financeira
The company reported revenue of $7.70M over the trailing twelve months, yet posted a net income loss of $-33,376,000 and an EBITDA of $-33,342,000, revealing a cost structure where expenses significantly exceed current income streams. Free cash flow stands at $-24,904,624, which signifies a heavy reliance on external capital sources to fund operations and research initiatives rather than internal cash generation. Gross margin is recorded at -270.8%, operating margin at -224.2%, and profit margin at 0.0%, indicating that the company's operational costs, particularly in research and development, are substantially higher than its revenue generation at this stage. Total cash on hand amounts to $27.50M against total debt of $22.96M, resulting in a debt-to-equity ratio of 86.62, which suggests a leveraged balance sheet typical for capital-intensive biotech firms but with manageable short-term obligations given the liquidity position. The current ratio is 3.59, demonstrating robust short-term liquidity as current assets exceed current liabilities by a wide margin. Return on equity is -79.7% and return on assets is -27.7%, metrics that reflect the substantial capital deployment required in clinical-stage development before positive returns can be realized by management.
Avaliação de valorização
The trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is listed as -0.18, implying that the market currently prices the stock based on future expectations rather than historical profitability. The price-to-book ratio is 0.33, indicating that the market values the company at significantly less than its net book value, a common characteristic for biotech firms with intangible assets not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1.13 and an EV/EBITDA of -0.12 suggest the market is pricing the asset based on revenue potential rather than earnings power. The stock has traded between a 52-week high of $9.24 and a 52-week low of $3.91, providing a historical range for volatility analysis. The beta value of 0.86 indicates that the stock's price volatility is slightly lower than the broader market, suggesting moderate sensitivity to general market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning historical growth rates cannot be calculated from the available data to compare earnings expansion against revenue expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that all available earnings are retained to fund ongoing research and development efforts. Consequently, the firm reinvests its financial resources directly into the growth of its clinical pipeline rather than distributing income to shareholders. The overall growth and income profile reflects a classic early-stage biotechnology company that prioritizes capital expenditure for product development over immediate shareholder returns or historical revenue expansion metrics.